TGFbetaR-KO CAR-EGFR T-cells

N/A

Report date: 2025/01/26 16:21:02

Base Information

Drug NameTGFbetaR-KO CAR-EGFR T-cells
Drug Alias Nameanti-EGFR CAR T-cell therapy (Chinese PLA General Hospital)anti-EGFR CAR T-cell therapy (Chinese PLA General Hospital)CRISPR/Cas9-mediated TGF-beta receptor II knockout anti-EGFR CAR T-cell therapy (Chinese PLA General Hospital)CAR-EGFR-TGFbetaR-KO T-cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulators
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsBile Duct Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesPla General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesPla General Hospital
Inactive CompaniesN/A
Active IndicationsBile Duct Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A